Core Viewpoint - Baixinan-B (02185) experienced a significant increase of over 52% in stock price, reaching HKD 9.22 with a trading volume of HKD 98.296 million, following the announcement of its Iberis RDN system receiving a 5-year healthcare qualification in France [1] Group 1: Product Development and Market Expansion - The Iberis RDN system has been granted a 5-year healthcare qualification by French authorities, with the potential for renewal, enhancing the clinical application support system in Europe [1] - The company has also secured clinical application and guideline recommendations in Italy, Germany, and Spain [1] - In July, media reports indicated that the U.S. CMS proposed to include RDN in the healthcare coverage for patients with uncontrolled hypertension [1] Group 2: Clinical Success and Market Potential - In February, Baixinan's subsidiary, Shanghai Antong Medical, completed the first commercial procedure of the Iberis RDN system in Germany [1] - According to CITIC Securities, the RDN procedure shows significant and long-term effective blood pressure reduction, with a simple operation and low complication rates, indicating a broad long-term market potential [1] - The company's RDN products are advancing commercialization simultaneously in domestic and international markets, with a focus on the results of the first year of commercialization in 2025 [1]

消息面上，7月15日，百心安旗下铂睿时Iberis RDN 系统获得法国官方给予为期5年的医保资格（且具备 续签资质），在欧洲临床应用支持体系的进一步完善。此外，公司已经在意大利、德国、西班牙获得临 床应用和指南推荐方案；7月有媒体报道称，美国CMS发布新提案，建议将RDN纳入未控制高血压患者 的医保覆盖范围。 值得注意的是，今年2月，百心安附属上海安通医疗研发的Iberis多极肾动脉射频消融系统(IberisRDN系 统)在德国完成首例商业化手术。中信建投指出，RDN降压效果显著且长期有效，术式操作简单并发症 概率低，长期市场空间广阔；百心安RDN产品目前在国内外同步推进商业化，建议关注公司25年首年 商业化成果。 智通财经APP获悉，百心安-B(02185)尾盘涨超52%，截至发稿，涨52.15%，报9.22港元，成交额9829.61 万港元。 ...